Clinical trial

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

NCT01276769

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2008-01-01

PhasePHASE2

Study timeline

Study start (unknown)2008-01-01Date precision: month

Registry last updated2011-11-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancerunresolved

Interventions

Paclitaxel plus carboplatinDRUG

Paclitaxel and epirubicinDRUG

Sponsors & collaborators

Chinese Academy of Medical Scienceslead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01276769 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.